Reported revenues of $281.6 million in Q4 and $1,088.7 million in fiscal year 2026Diluted EPS of $3.91 and Adjusted Diluted EPS of $4.38 in fiscal year 2026Announces agreement to acquire LaCorium Health, a leader in Australian therapeutic skin careIntroducing Outlook for Fiscal 2027 Organic Revenue Growth and Adjusted Diluted EPS of 1% to 3%, respectively, excluding the impact of acquisitions TARRYTOWN, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financ ...